| Gene symbol | AKT1 | Synonyms | AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA | Type of gene | protein-coding |
| Chromosome | 14 | Map location | 14q32.33 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | AKT serine/threonine kinase 1 | ||||
| GTO ID | GTC2954 |
| Trial ID | NCT05267899 |
| Disease | Advanced Solid Tumor |
| Altered gene | Akt-1 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | WGI-0301 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase I, First in Human, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301, a Lipid Nanoparticle Suspension of Akt-1 Antisense Oligonucleotide, in Patients With Advanced Solid Tumors |
| Year | 2022 |
| Country | United States |
| Company sponsor | Zhejiang Haichang Biotech Co., Ltd. |
| Other ID(s) | WGI0301-P1U |
| Vector information | |||
|
|||
| Cohort 1 | |||||
|
|||||